About This Page
This is a clinician-written, evidence-based guide aligned to the MCC Examination Objectives. It is structured by clinical presentation — the way the MCCQE tests and the way patients actually present. Management reflects current Canadian guidelines (CMA, CFPC, CPS). Always cross-reference with institutional protocols and clinical judgment.
The Bottom Line
- Fever may be the only sign of serious infection in neutropenia or immunosuppression
- Febrile neutropenia is an oncologic emergency: cultures promptly and empiric anti-pseudomonal antibiotics rapidly
- The differential depends on the immune defect: neutropenia, T-cell impairment, asplenia and lines each predict different pathogens
- Ask about chemotherapy timing, transplant, biologics, steroids, HIV/CD4 count, asplenia, lines and prophylaxis
- Many immunocompromised febrile patients require ED assessment, isolation, cultures and specialist input
Approach to the Presentation
The presentation is defined by host vulnerability. Immunocompromised patients may deteriorate quickly and may lack typical inflammatory signs. Define the immune defect: neutropenia from chemotherapy, hematologic malignancy, solid organ or stem-cell transplant, advanced HIV, high-dose corticosteroids, biologic therapy, asplenia, renal failure, cirrhosis or indwelling vascular access. Fever in neutropenia is time-critical because bloodstream infection can progress rapidly. Canadian provincial cancer agencies and Cancer Care Ontario emphasise early recognition, cultures, empiric broad-spectrum therapy, risk assessment and outpatient care only for carefully selected low-risk patients.
Differential Diagnosis
| diagnosis | likelihood | key features | distinguishing test |
|---|---|---|---|
| Febrile neutropenia with Gram-negative bacteremia | must-not-miss | Recent chemotherapy, ANC <0.5 x 10^9/L or expected decline, fever, rigors, hypotension, mucositis or central line | CBC differential confirming neutropenia plus blood cultures; treat before culture results |
| Central line-associated bloodstream infection | must-not-miss | Fever/rigors with port/PICC/CVC, line tenderness, erythema or symptoms during flushing | Peripheral and line blood cultures; differential time to positivity |
| Invasive fungal infection | must-not-miss | Persistent fever despite antibiotics, prolonged neutropenia, transplant, steroids, pulmonary nodules, sinus symptoms or pleuritic pain | CT chest/sinuses, fungal biomarkers where used, bronchoscopy/tissue culture |
| Pneumocystis jirovecii pneumonia | must-not-miss | Advanced HIV, transplant, prolonged high-dose steroids or biologics with fever, dry cough, dyspnea and hypoxia | CT chest with ground-glass changes; induced sputum/BAL PCR or immunofluorescence |
| Bacterial pneumonia | common | Fever with cough, dyspnea or hypoxia; infiltrates may be subtle early in neutropenia | CXR or CT chest; blood/sputum cultures if severe |
| Clostridioides difficile infection | common | Recent antibiotics, healthcare exposure or chemotherapy with watery diarrhoea, abdominal pain and fever | Stool toxin/NAAT according to local algorithm |
| Disseminated herpesvirus infection | less common | Transplant, advanced HIV or chemotherapy with vesicular rash, hepatitis, pneumonitis, colitis, retinitis or encephalitis | PCR from lesion, blood, CSF or organ-specific testing |
| Opportunistic TB or nontuberculous mycobacteria | less common | Advanced HIV, TNF-alpha inhibitor or transplant with fever, weight loss, night sweats or disseminated disease | AFB smear/culture/NAAT from respiratory or involved tissue |
| Drug fever / infusion reaction | less common | Temporal relationship to chemotherapy, biologic, antibiotic, transfusion or immune therapy | Diagnosis of exclusion after infection ruled out |
| Immune reconstitution inflammatory syndrome | rare | Recent ART initiation with advanced HIV and paradoxical worsening of TB, cryptococcus or MAC | Clinical context plus identification of underlying pathogen |
Red Flags & Key History
Symptoms
Any fever in a patient on chemotherapy with possible neutropenia
Rigors, hypotension, altered mental status, hypoxia, tachypnoea or poor perfusion
Indwelling line, port, dialysis access, transplant, high-dose steroids, biologics or asplenia
Pleuritic pain, sinus pain, haemoptysis or persistent fever despite antibiotics
Dry cough and progressive exertional dyspnea in advanced HIV or prolonged steroid use
Mucositis, perianal pain, abdominal pain, diarrhoea or skin breakdown may be the only source clues
Signs
ANC <0.5 x 10^9/L or expected decline below this level
Line erythema, tunnel tenderness, fluctuance or rigors during line use
Hypoxia out of proportion to chest findings
Vesicular rash, oral/genital ulcers, retinitis symptoms, meningism or focal neurological deficit
Perianal tenderness or cellulitis can represent deep infection without abscess formation in neutropenia
Approach to Investigation
First-line
CBC with differential urgentlyDetermine ANC; neutropenia changes urgency and empiric coverage
Blood cultures before antibiotics if this does not delay therapyAt least two sets; include peripheral and central-line cultures if line present
Electrolytes, creatinine, liver enzymes, bilirubin, lactate if unwellGuides severity, organ dysfunction, dosing and sepsis assessment
Urinalysis/urine culture, CXR, respiratory viral testingCommon first-line investigations in febrile neutropenia
Culture focal sitesSputum, wound, stool, CSF, line site or skin lesion depending on symptoms
Second-line
CT chest/sinuses/abdomen/pelvisIf persistent fever, focal symptoms, suspected fungal infection, abdominal pain or unclear source
PJP testingInduced sputum or BAL PCR/immunofluorescence when suspected
CMV/EBV/HSV/VZV PCR and fungal biomarkersUse based on transplant status, immune defect and local specialist protocols
Lumbar punctureIf meningitis/encephalitis suspected; do not delay empiric CNS therapy in an unstable patient
Specialist
Oncology/hematology consultationFor febrile neutropenia, chemotherapy complications, risk stratification and disposition
Infectious diseases consultationFor transplant, prolonged neutropenia, opportunistic infection, resistant organisms or complex prophylaxis/treatment decisions
Management Principles
Cancer Care Ontario febrile neutropenia guidance + PHAC/AMMI Canada infectious disease principles1
Febrile neutropenia
- Treat as an emergency; assess ABCs and sepsis features
- Obtain CBC differential, blood cultures and source-directed cultures promptly
- Start empiric anti-pseudomonal IV therapy rapidly after cultures when feasible; common Canadian regimens include piperacillin-tazobactam or cefepime depending on local protocol
- Add vancomycin only for line, skin/soft tissue, pneumonia, severe mucositis, instability or MRSA risk
2
Risk stratification and disposition
- High-risk features include unstable vitals, pneumonia, abdominal pain, renal/hepatic dysfunction, prolonged profound neutropenia, acute leukemia, transplant or poor support
- Selected low-risk oncology patients may be outpatient only under a formal cancer-centre protocol
- Do not discharge a febrile neutropenic patient from primary care without oncology/ED assessment
3
Non-neutropenic immunocompromise
- Define immune defect and likely pathogens before choosing therapy
- Use isolation precautions when transmissible infection is possible
- Review prophylaxis, vaccination status and drug interactions
4
Reassessment
- Escalate if fever persists beyond 48-72 hours or patient deteriorates
- Consider fungal, viral, line, abscess and non-infectious causes when cultures are negative
- De-escalate antimicrobials when safe
Complications & Pitfalls
- False reassurance from normal exam: Neutropenic patients may not form pus or focal inflammatory signs.
- Waiting for ANC: Recent chemotherapy and fever should be managed urgently while counts are confirmed.
- Overusing vancomycin: Gram-positive coverage is not automatic.
- Missing PJP: Hypoxia with dry cough may have a normal early CXR.
- Drug interactions: ART, azoles, macrolides, calcineurin inhibitors and chemotherapy interact substantially.
MCCQE1 Exam Tips
- 1Fever after chemotherapy equals febrile neutropenia until proven otherwise
- 2Do not be reassured by lack of localizing symptoms in neutropenia
- 3Ask which immune arm is impaired: neutrophils, T cells, B cells, complement/asplenia or barriers/lines
- 4PJP clue: dry cough, progressive dyspnea and hypoxia in advanced HIV/steroids/transplant
- 5Vancomycin is not routine for all febrile neutropenia
- 6Outpatient febrile neutropenia management is only for selected low-risk patients under a clear oncology pathway
practicetest your knowledge on fever in the immunocompromised hostApply what you've learnt with MCCQE1-style questions from the iatroX Q-Bank — infectious disease and beyond.
open q-bank